Gene Medicine
3 known investors
Korean biotech developing next-generation oncolytic viruses for hard-to-treat cancers, with CDMO/CMO services.
Also known as (주)진메디신 · Genemedicine · GeneMedicine · Jin Medicine
Investors · 3
Company profile
researched Aug 2026Gene Medicine (Genemedicine, corporate name (주)진메디신) is a South Korean biotechnology company focused on developing next-generation oncolytic (anti-cancer) viruses intended to treat patients with refractory, hard-to-treat cancers. The company organizes its research and development around a proprietary oncolytic virus platform ("GM oncolytic virus") and an associated platform technology, and presents a clinical/preclinical pipeline comprising the candidates GM101, GM102, GM103 and GM104.
Alongside its internal drug development programs, the company operates a CDMO/CMO business, offering contract development and manufacturing activities. Corporate materials also reference advisory board members, awards and certifications, and partnership activity. The company is headquartered in Seoul, at the Hanyang University Fusion Tech Center (FTC building), 7th floor, room 707, 222 Wangsimni-ro, Seongdong-gu, Seoul.
Business model
The company combines proprietary therapeutic development of oncolytic virus candidates with a CDMO/CMO service line providing contract development and manufacturing to external clients.
Latest developments
Company notices posted on the corporate site include announcements of a new share issuance (2026-03), convocation of the 12th regular general shareholders' meeting (2026-04) and convocation of an extraordinary general shareholders' meeting (2026-06).
▸Full profile — technology, go-to-market, geography
Technology
The core technology is an oncolytic virus platform branded as the GM oncolytic virus, supported by additional platform technology used to generate the GM101, GM102, GM103 and GM104 pipeline candidates for oncology indications.
Go-to-market
Patients with refractory or hard-to-treat cancers for the therapeutic pipeline, and biopharmaceutical clients requiring contract development and manufacturing services.
Geography
Based in Seoul, South Korea, in the Hanyang University Fusion Tech Center in Seongdong-gu; the corporate website is published in Korean with an English option.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 3
launches, deals, and filingsThe company issued a convocation notice for an extraordinary general meeting of shareholders.
The company issued a convocation notice for its 12th regular general meeting of shareholders.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Gene Medicinegene-medicine.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Gene Medicine do?
- Korean biotech developing next-generation oncolytic viruses for hard-to-treat cancers, with CDMO/CMO services.
- Who are Gene Medicine's investors?
- Gene Medicine's investors include Atinum Investment Co. Ltd., IMM Investment Japan, LB Investment.